HDAC9 and breast carcinoma: Our previous studies have shown that HDAC inhibitors (e.g. valproic acid,vorinostat, and entinostat) enhance the anti-tumor activity of tamoxifen inER-positive breast cancer cells, by both reducing cell proliferation andincreasing cell death [6,7].